Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

키워드

참고문헌 (18)

1. Michael H. Le, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach", Clinical and Molecular Hepatology, 28(4), pp.841~850 (2022), 대한간학회
2. Fabbrini E, "Obesity and nonalcoholic fatty liver disease : biochemical, metabolic, and clinical implications", Hepatology, 51, pp.679~689 (2010)
3. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
4. Tang A, "Comparative burden of metabolic dysfunction in lean NAFLD vs Non-lean NAFLD-A systematic review and metaanalysis", Clin Gastroenterol Hepatol (2022)[DOI]
5. Hagström H, "Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease : A long-term followup study", Hepatol Commun, 2, pp.48~57 (2017)
6. Wah-Kheong Chan, "Comparison between obese and non-obese nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.58~67 (2023), 대한간학회
7. Staufer K, "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed nonalcoholic fatty liver disease", J Hepatol, 77, pp.918~930 (2022)
8. Sae Kyung Joo, "Interaction between sarcopenia and nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.68~78 (2023), 대한간학회
9. Sinn DH, "Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass : A longitudinal cohort study", Hepatology, 76, pp.1746~1754 (2022)
10. Seul Ki Han, "Non-alcoholic fatty liver disease: Definition and subtypes", Clinical and Molecular Hepatology, 29, pp.5~16 (2023), 대한간학회
11. Eslam M, "Genetics and epigenetics of NAFLD and NASH : Clinical impact", J Hepatol, 68, pp.268~279 (2018)
12. Lin H, "Association of genetic variations with NAFLD in lean individuals", Liver Int, 42, pp.149~160 (2022)
13. Wong VW, "Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease", J Hepatol, 69, pp.1349~1356 (2018)
14. Chun HS, "Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 21, pp.358~369 (2023)
15. Jihyun An, "Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials", Clinical and Molecular Hepatology, 29, pp.268~275 (2023), 대한간학회
16. Eslamparast T, "Synbiotic supplementation in nonalcoholic fatty liver disease : a randomized, double-blind, placebo-controlled pilot study", Am J Clin Nutr, 99, pp.535~542 (2014)
17. Lei Miao, "Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review", Clinical and Molecular Hepatology, 28(4), pp.725~738 (2022), 대한간학회
18. Ratziu V, "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159 (2016)

관련 논문AI추천